레프숨병 치료 시장, 점유율, 규모, 동향, 산업 분석 리포트 : 유형별, 최종사용자별, 연령층별, 지역별, 부문별 예측(2023-2032년)

The global refsum disease treatment market size is expected to reach USD 2.55 billion by 2032, according to a new study by Polaris Market Research. The report "Refsum Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Surgery and Medication); By End User (Hospitals, Clinics, Research Centers, Homecare); By Age Group; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing knowledge and awareness about genetic and rare disorders and their available treatment options and the rapid increase in global population, along with the surging government support and rising funding for the development of new and more enhanced treatment options with higher accuracy and low costs, are among the prominent factors driving the market growth. Additionally, the proliferation of research into the pathophysiology of refsum disease that could lead to a better understanding of the condition and the development of potential treatment targets, along with the increase in government approvals for various gene therapies, is likely to foster the global market positively.

For instance, in May 2023, Atsena Therapeutics announced that they had successfully received authorization from the US Food and Drug Administration for the launch of their phase 1/2 clinical trial of X-linked retinoschisis gene therapy.

Growing advances in genetic testing and molecular profiling, which allow for a more personalized approach to treatment and increasing proliferation for tailoring therapies to an individual's specific genetic profile and disease characteristics that can lead to more effective and targeted interventions, are likely to open up new growth avenues and opportunities in the near future.

Surging personalized medicine approaches across the globe, which basically involve tailoring treatment plans to individual patient profiles with advancements in genetic testing and molecular profiling, results in more targeted and effective interventions for patients with rare diseases like refsum.

There has been a surge in the number of startups and new companies trying to enter the market and are investing huge amounts in R&D to ensure more effective & efficient treatment solutions for patients. They are also working on several clinical trials and medical research to provide advancements in existing treatment techniques and, thus, looking to secure their position in the global market.

Refsum Disease Treatment Market Report Highlights

• The surgery segment accounted for noteworthy market share on account of the rising need for effective surgical solutions among patients with rare disorders like refsum

• The hospitals segment led the industry market with a substantial share due to the presence of several advanced equipped and diagnostic techniques in hospitals

• The adults segment will grow at the fastest rate, which is mainly attributed to the growing global adult population and the number of people suffering from different rare diseases

• North America dominated the market on account of the presence of well-established healthcare infrastructure and awareness about the availability of treatment options

• The key market players include Ceuta Healthcare, Illumina, Nurotron Biotechnology, William Demant Holding, Cochlear, & BioRad Laboratories

Polaris Market Research has segmented the refsum disease treatment market report based on type, end user, age group, and region:

Refsum Disease Treatment, Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Surgery
• Medication

Refsum Disease Treatment, End User Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals
• Clinics
• Research Centers
• Homecare

Refsum Disease Treatment, Age Group Outlook (Revenue - USD Billion, 2019 - 2032)

• Pediatric
• Adults

Refsum Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Refsum Disease Treatment Market Insights

• 4.1. Refsum Disease Treatment Market - End User Snapshot
• 4.2. Refsum Disease Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing concerns related to various rare and genetic disorders
    • 4.2.1.2. Advancements in medical research and therapeutics
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High treatment costs and limited accessibility
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Refsum Disease Treatment Market End User Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Refsum Disease Treatment Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
• 5.3. Surgery
  • 5.3.1. Global Refsum Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
• 5.4. Medication
  • 5.4.1. Global Refsum Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)

6. Global Refsum Disease Treatment Market, by Age Group

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
• 6.3. Pediatric
  • 6.3.1. Global Refsum Disease Treatment Market, by Pediatric, by Region, 2019-2032 (USD Billion)
• 6.4. Adults
  • 6.4.1. Global Refsum Disease Treatment Market, by Adults, by Region, 2019-2032 (USD Billion)

7. Global Refsum Disease Treatment Market, by End User

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
• 7.3. Hospitals
  • 7.3.1. Global Refsum Disease Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
• 7.4. Clinics
  • 7.4.1. Global Refsum Disease Treatment Market, by Clinics, By Region, 2019-2032 (USD Billion)
• 7.5. Research Centers
  • 7.5.1. Global Refsum Disease Treatment Market, by Research Centers, By Region, 2019-2032 (USD Billion)
• 7.6. Homecare
  • 7.6.1. Global Refsum Disease Treatment Market, by Homecare, By Region, 2019-2032 (USD Billion)

8. Global Refsum Disease Treatment Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Refsum Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
• 8.3. Refsum Disease Treatment Market - North America
  • 8.3.1. North America: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
  • 8.3.2. North America: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
  • 8.3.3. North America: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.3.4. Refsum Disease Treatment Market - U.S.
    • 8.3.4.1. U.S.: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.3.4.2. U.S.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.3.4.3. U.S.: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.3.5. Refsum Disease Treatment Market - Canada
    • 8.3.5.1. Canada: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.3.5.2. Canada.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.3.5.3. Canada: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
• 8.4. Refsum Disease Treatment Market - Europe
  • 8.4.1. Europe: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
  • 8.4.2. Europe.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
  • 8.4.3. Europe: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.4. Refsum Disease Treatment Market - UK
    • 8.4.4.1. UK: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.4.2. UK.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.4.3. UK: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.5. Refsum Disease Treatment Market - France
    • 8.4.5.1. France: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.5.2. France.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.5.3. France: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.6. Refsum Disease Treatment Market - Germany
    • 8.4.6.1. Germany: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.6.2. Germany.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.6.3. Germany: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.7. Refsum Disease Treatment Market - Italy
    • 8.4.7.1. Italy: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.7.2. Italy.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.7.3. Italy: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.8. Refsum Disease Treatment Market - Spain
    • 8.4.8.1. Spain: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.8.2. Spain.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.8.3. Spain: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.9. Refsum Disease Treatment Market - Netherlands
    • 8.4.9.1. Netherlands: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.9.2. Netherlands.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.9.3. Netherlands: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.4.10. Refsum Disease Treatment Market - Russia
    • 8.4.10.1. Russia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.10.2. Russia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.4.10.3. Russia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
• 8.5. Refsum Disease Treatment Market - Asia Pacific
  • 8.5.1. Asia Pacific: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
  • 8.5.2. Asia Pacific.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
  • 8.5.3. Asia Pacific: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.4. Refsum Disease Treatment Market - China
    • 8.5.4.1. China: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.4.2. China.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.4.3. China: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.5. Refsum Disease Treatment Market - India
    • 8.5.5.1. India: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.5.2. India.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.5.3. India: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.6. Refsum Disease Treatment Market - Malaysia
    • 8.5.6.1. Malaysia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.6.2. Malaysia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.6.3. Malaysia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.7. Refsum Disease Treatment Market - Japan
    • 8.5.7.1. Japan: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.7.2. Japan.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.7.3. Japan: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.8. Refsum Disease Treatment Market - Indonesia
    • 8.5.8.1. Indonesia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.8.2. Indonesia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.8.3. Indonesia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.5.9. Refsum Disease Treatment Market - South Korea
    • 8.5.9.1. South Korea: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.9.2. South Korea.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.5.9.3. South Korea: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
• 8.6. Refsum Disease Treatment Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
  • 8.6.2. Middle East & Africa.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
  • 8.6.3. Middle East & Africa: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.6.4. Refsum Disease Treatment Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.4.2. Saudi Arabia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.6.5. Refsum Disease Treatment Market - UAE
    • 8.6.5.1. UAE: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.5.2. UAE.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.6.5.3. UAE: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.6.6. Refsum Disease Treatment Market - Israel
    • 8.6.6.1. Israel: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.6.2. Israel.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.6.6.3. Israel: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.6.7. Refsum Disease Treatment Market - South Africa
    • 8.6.7.1. South Africa: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.7.2. South Africa.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.6.7.3. South Africa: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
• 8.7. Refsum Disease Treatment Market - Latin America
  • 8.7.1. Latin America: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
  • 8.7.2. Latin America.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
  • 8.7.3. Latin America: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.7.4. Refsum Disease Treatment Market - Mexico
    • 8.7.4.1. Mexico: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.4.2. Mexico.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.7.4.3. Mexico: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.7.5. Refsum Disease Treatment Market - Brazil
    • 8.7.5.1. Brazil: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.5.2. Brazil.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.7.5.3. Brazil: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
  • 8.7.6. Refsum Disease Treatment Market - Argentina
    • 8.7.6.1. Argentina: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.6.2. Argentina.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
    • 8.7.6.3. Argentina: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Agilent Technologies
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. B. Braun Medical Inc.
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. BioRad Laboratories Inc.
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Ceuta Healthcare Limited
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Cochlear Ltd.
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Cook
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Fresenius Kabi
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Igenomix
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Illumina Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Medline Industries Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Nurotron Biotechnology Co. Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Sequenom
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Sonova
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. William Demant Holding A/S
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development